Systematic Literature Review of the Economic Burden of Celiac Disease.
Elizabeth S MearnsAliki TaylorTalia BoulangerKelly Jean Thomas CraigMichele GerberDaniel A LefflerJennifer DrahosDavid S SandersBenjamin LebwohlPublished in: PharmacoEconomics (2020)
Most of the few available economic studies of CD assess testing and diagnosis costs, especially in Europe. Methods of testing generally are considered cost effective when they combine diagnostic modalities in symptomatic patients. Most costs to a payer of managing CD derive from outpatient care. Following GFD initiation, patients lose fewer days from work and school than pretreatment.